Skip to content
type1.science
ObservationalRecruitingNCT04039945

Fr1da: General-population infant/child islet-autoantibody screening (Bavaria)

A landmark public-health program that screens young children across Bavaria for the islet autoantibodies that mark early-stage type 1 diabetes, before any symptoms appear. It showed population-wide screening is feasible and that children caught early almost never arrive at clinical diagnosis in dangerous diabetic ketoacidosis.

Primary endpoints

  • Presence of multiple islet autoantibodies (two or more of IAA, GADA, IA-2A, ZnT8A), defining presymptomatic (early-stage) type 1 diabetes
  • Prevalence of presymptomatic type 1 diabetes in the screened population
  • Feasibility of population-based screening within routine primary care
  • Frequency of diabetic ketoacidosis at clinical diagnosis
  • Parental psychological stress after an early diagnosis

Results so far

Of 90,632 children screened in the first analysis, 0.31% had presymptomatic type 1 diabetes (two or more islet autoantibodies). Capillary finger-prick sampling worked in over 99% of children, showing routine-care screening is feasible. Among children who progressed to clinical diabetes, only 2 developed diabetic ketoacidosis — far below the roughly 20% (Germany) to 40% (US) seen in unscreened children. The 3-year risk of progressing to clinical (stage 3) diabetes among those with early-stage disease was about 25%. Parental stress rose briefly at diagnosis but fell over 12 months of follow-up.

The full picture

What Fr1da is, and why it matters

Type 1 diabetes does not start the day a child gets sick. Years earlier, the immune system begins attacking the insulin-making cells, and this leaves a fingerprint in the blood: "islet autoantibodies." When a child has two or more of these autoantibodies, they have early-stage type 1 diabetes and will almost certainly go on to need insulin — it is essentially a matter of when, not if.1

Fr1da is a public-health program in Bavaria, Germany, that tests young children for these autoantibodies during ordinary pediatrician visits, long before symptoms appear.2 The goal is to catch the disease early so families can prepare, avoid a dangerous crisis at diagnosis, and become eligible for prevention trials.2

Who it's for and how it's designed

This is general-population screening — any child can take part, regardless of family history.3 It is an observational program (no drug is tested in the screening itself), run by the Helmholtz Zentrum München diabetes-research institute and led by Prof. Anette-Gabriele Ziegler.4 The core test was offered to children roughly aged 2-5 at routine well-child visits, using a simple finger-prick (capillary) blood sample; the program has since expanded to more ages and regions.34 Children found to have multiple autoantibodies are invited for metabolic staging, diabetes education, and ongoing monitoring.1 Hundreds of thousands of children have been screened, and the program is still recruiting, with follow-up planned to continue for years.4

Key results

In the first major analysis, 90,632 children were screened, and 0.31% had presymptomatic type 1 diabetes.1 The finger-prick approach worked in more than 99% of children, showing that population screening within routine care is genuinely feasible.3 Crucially, among children who went on to clinical diabetes, only 2 arrived in diabetic ketoacidosis (DKA) — a life-threatening emergency — compared with the roughly 20% in Germany and 40% in the US seen in unscreened children.1 Among those with early-stage disease, the 3-year risk of progressing to clinical diabetes was about 25%.1 Parents' stress rose briefly after diagnosis but declined over the following year.1 Later work refined the staging, identifying substages with very different 2-year progression risks.5

What it means and what's next

Fr1da proved that you can screen a whole population of children for type 1 diabetes and that doing so dramatically reduces dangerous DKA at onset.1 It now serves as a blueprint for national and international screening efforts and as a pipeline of early-stage children who may benefit from disease-delaying immune therapies.5

References

  1. Ziegler AG, et al. Yield of a Public Health Screening of Children for Islet Autoantibodies in Bavaria, Germany. JAMA (2020). https://pmc.ncbi.nlm.nih.gov/articles/PMC6990943/ ↩ ↩2 ↩3 ↩4 ↩5 ↩6 ↩7

  2. Raab J, et al. Capillary blood islet autoantibody screening for identifying pre-type 1 diabetes in the general population: design and initial results of the Fr1da study. BMJ Open (2016). https://pmc.ncbi.nlm.nih.gov/articles/PMC4874167/ ↩ ↩2

  3. Raab J, et al. Design and initial results of the Fr1da study (feasibility and capillary sampling). BMJ Open (2016). https://pmc.ncbi.nlm.nih.gov/articles/PMC4874167/ ↩ ↩2 ↩3

  4. Fr1da: Early Diagnosis and Care of Type 1 Diabetes. ClinicalTrials.gov NCT04039945 (accessed 2026). https://clinicaltrials.gov/study/NCT04039945 ↩ ↩2 ↩3

  5. Weiss A, et al. Progression likelihood score identifies substages of presymptomatic type 1 diabetes in childhood public health screening. Diabetologia (2022). https://pmc.ncbi.nlm.nih.gov/articles/PMC9630406/ ↩ ↩2